<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS156047</article-id><article-id pub-id-type="doi">10.1101/2022.10.20.512999</article-id><article-id pub-id-type="archive">PPR560668</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Altered infective competence of the human gut microbiome in COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>de Nies</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Galata</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Martin-Gallausiaux</surname><given-names>Camille</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Despotovic</surname><given-names>Milena</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Busi</surname><given-names>Susheel Bhanu</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Snoeck</surname><given-names>Chantal J.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Delacour</surname><given-names>Lea</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Budagavi</surname><given-names>Deepthi Poornima</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Laczny</surname><given-names>Cédric Christian</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Habier</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lupu</surname><given-names>Paula-Cristina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Halder</surname><given-names>Rashi</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fritz</surname><given-names>Joёlle V.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>Taina</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sandt</surname><given-names>Estelle</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>O’Sullivan</surname><given-names>Marc Paul</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Soumyabrata</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Satagopam</surname><given-names>Venkata</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><collab>CON-VINCE Consortium
<contrib-group><contrib contrib-type="author"><name><surname>Acharya</surname><given-names>Geeta</given-names></name><aff id="A14">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Aguayo</surname><given-names>Gloria</given-names></name><aff id="A15">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Ammerlaan</surname><given-names>Wim</given-names></name><aff id="A16">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Assele-Kama</surname><given-names>Ariane</given-names></name><aff id="A17">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Bahlawane</surname><given-names>Christelle</given-names></name><aff id="A18">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Beaumont</surname><given-names>Katy</given-names></name><aff id="A19">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Beaupain</surname><given-names>Nadia</given-names></name><aff id="A20">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Beckers</surname><given-names>Lucrèce</given-names></name><aff id="A21">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Bellora</surname><given-names>Camille</given-names></name><aff id="A22">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Betsou</surname><given-names>Fay</given-names></name><aff id="A23">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Boly</surname><given-names>Sandie</given-names></name><aff id="A24">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>Dirk</given-names></name><aff id="A25">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Charalambous</surname><given-names>Eleftheria</given-names></name><aff id="A26">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Charpentier</surname><given-names>Emilie</given-names></name><aff id="A27">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Counson</surname><given-names>Manuel</given-names></name><aff id="A28">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Witt</surname><given-names>Brian De</given-names></name><aff id="A29">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Domingues</surname><given-names>Olivia</given-names></name><aff id="A30">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Dording</surname><given-names>Claire</given-names></name><aff id="A31">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Dragomir</surname><given-names>Bianca</given-names></name><aff id="A32">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Fautsch</surname><given-names>Tessy</given-names></name><aff id="A33">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Ferrand</surname><given-names>Jean-Yves</given-names></name><aff id="A34">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>Ana Festas</given-names></name><aff id="A35">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Véronique Fritz</surname><given-names>Joёlle</given-names></name><aff id="A36">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Gantenbein</surname><given-names>Manon</given-names></name><aff id="A37">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Georges</surname><given-names>Laura</given-names></name><aff id="A38">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Graas</surname><given-names>Jérôme</given-names></name><aff id="A39">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hamot</surname><given-names>Gael</given-names></name><aff id="A40">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hanff</surname><given-names>Anne-Marie</given-names></name><aff id="A41">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Maxime</given-names></name><aff id="A42">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hefele</surname><given-names>Lisa</given-names></name><aff id="A43">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Henry</surname><given-names>Estelle</given-names></name><aff id="A44">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Henry</surname><given-names>Margaux</given-names></name><aff id="A45">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Herkenne</surname><given-names>Eve</given-names></name><aff id="A46">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hilger</surname><given-names>Christiane</given-names></name><aff id="A47">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hübschen</surname><given-names>Judith</given-names></name><aff id="A48">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Huiart</surname><given-names>Laetitia</given-names></name><aff id="A49">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hundt</surname><given-names>Alexander</given-names></name><aff id="A50">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Iserentant</surname><given-names>Gilles</given-names></name><aff id="A51">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Kler</surname><given-names>Stéphanie</given-names></name><aff id="A52">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Krüger</surname><given-names>Rejko</given-names></name><aff id="A53">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lambert</surname><given-names>Pauline</given-names></name><aff id="A54">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lehmann</surname><given-names>Sabine</given-names></name><aff id="A55">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lemaire</surname><given-names>Morgane</given-names></name><aff id="A56">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lumley</surname><given-names>Andrew</given-names></name><aff id="A57">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Marchese</surname><given-names>Monica</given-names></name><aff id="A58">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Mériaux</surname><given-names>Sophie</given-names></name><aff id="A59">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Minelli</surname><given-names>Maura</given-names></name><aff id="A60">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Mousel</surname><given-names>Alessandra</given-names></name><aff id="A61">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Munsch</surname><given-names>Maeva</given-names></name><aff id="A62">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Neumann</surname><given-names>Mareike</given-names></name><aff id="A63">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Ollert</surname><given-names>Markus</given-names></name><aff id="A64">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>O’Sullivan</surname><given-names>Marc Paul</given-names></name><aff id="A65">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Perquin</surname><given-names>Magali</given-names></name><aff id="A66">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Pexaras</surname><given-names>Achilleas</given-names></name><aff id="A67">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Plesseria</surname><given-names>Jean-Marc</given-names></name><aff id="A68">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Remark</surname><given-names>Lucie</given-names></name><aff id="A69">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Sandt</surname><given-names>Estelle</given-names></name><aff id="A70">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Bruno</given-names></name><aff id="A71">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Sausy</surname><given-names>Aurélie</given-names></name><aff id="A72">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Schmitt</surname><given-names>Margaux</given-names></name><aff id="A73">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Seal</surname><given-names>Sneeha</given-names></name><aff id="A74">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Servais</surname><given-names>Jean-Yves</given-names></name><aff id="A75">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Simon</surname><given-names>Florian</given-names></name><aff id="A76">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Snoeck</surname><given-names>Chantal</given-names></name><aff id="A77">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Sokolowska</surname><given-names>Kate</given-names></name><aff id="A78">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Thien</surname><given-names>Hermann</given-names></name><aff id="A79">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Trouet</surname><given-names>Johanna</given-names></name><aff id="A80">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>Jonathan</given-names></name><aff id="A81">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Vaillant</surname><given-names>Michel</given-names></name><aff id="A82">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Esteves</surname><given-names>Daniela Valoura</given-names></name><aff id="A83">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Verschueren</surname><given-names>Charlène</given-names></name><aff id="A84">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Zamboni</surname><given-names>Tania</given-names></name><aff id="A85">Luxembourg Institute of Health, Strassen, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Alper</surname><given-names>Pinar</given-names></name><aff id="A86">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Gawron</surname><given-names>Piotr</given-names></name><aff id="A87">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Soumyabrata</given-names></name><aff id="A88">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Glaab</surname><given-names>Enrico</given-names></name><aff id="A89">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Gomes</surname><given-names>Clarissa</given-names></name><aff id="A90">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Ramos</surname><given-names>Borja Gomez</given-names></name><aff id="A91">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Gorgogietas</surname><given-names>Vyron</given-names></name><aff id="A92">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Groues</surname><given-names>Valentin</given-names></name><aff id="A93">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Wei</given-names></name><aff id="A94">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Heirendt</surname><given-names>Laurent</given-names></name><aff id="A95">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hemedan</surname><given-names>Ahmed</given-names></name><aff id="A96">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Herzinger</surname><given-names>Sascha</given-names></name><aff id="A97">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Kaysen</surname><given-names>Anne</given-names></name><aff id="A98">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lebioda</surname><given-names>Jacek Jaroslaw</given-names></name><aff id="A99">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>Tainà</given-names></name><aff id="A100">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Massart</surname><given-names>François</given-names></name><aff id="A101">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Patrick</given-names></name><aff id="A102">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Olesky</surname><given-names>Christiane</given-names></name><aff id="A103">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Satagopam</surname><given-names>Venkata P.</given-names></name><aff id="A104">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Pauly</surname><given-names>Claire</given-names></name><aff id="A105">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Pauly</surname><given-names>Laure</given-names></name><aff id="A106">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Pavelka</surname><given-names>Lukas</given-names></name><aff id="A107">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Meyers</surname><given-names>Guilherme Ramos</given-names></name><aff id="A108">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Rauschenberger</surname><given-names>Armin</given-names></name><aff id="A109">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Rommes</surname><given-names>Basile</given-names></name><aff id="A110">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Rump</surname><given-names>Kirsten</given-names></name><aff id="A111">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>Reinhard</given-names></name><aff id="A112">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Schröder</surname><given-names>Valerie</given-names></name><aff id="A113">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Skrozic</surname><given-names>Amna</given-names></name><aff id="A114">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Stute</surname><given-names>Lara</given-names></name><aff id="A115">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Toukourou</surname><given-names>Noua</given-names></name><aff id="A116">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Trefois</surname><given-names>Christophe</given-names></name><aff id="A117">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Moreno</surname><given-names>Carlos Vega</given-names></name><aff id="A118">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Vyas</surname><given-names>Maharshi</given-names></name><aff id="A119">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xinhui</given-names></name><aff id="A120">Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Leist</surname><given-names>Anja</given-names></name><aff id="A121">University of Luxembourg, Esch-sur-Alzette, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Lutz</surname><given-names>Annika</given-names></name><aff id="A122">University of Luxembourg, Esch-sur-Alzette, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Vögele</surname><given-names>Claus</given-names></name><aff id="A123">University of Luxembourg, Esch-sur-Alzette, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Linda</given-names></name><aff id="A124">Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Loureiro</surname><given-names>João Manuel</given-names></name><aff id="A125">Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Nicolai</surname><given-names>Beatrice</given-names></name><aff id="A126">Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Schweicher</surname><given-names>Alexandra</given-names></name><aff id="A127">Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Wauters</surname><given-names>Femke</given-names></name><aff id="A128">Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Abdelrahman</surname><given-names>Tamir</given-names></name><aff id="A129">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Coibion</surname><given-names>Estelle</given-names></name><aff id="A130">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Fournier</surname><given-names>Guillaume</given-names></name><aff id="A131">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Leick</surname><given-names>Marie</given-names></name><aff id="A132">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Mühlschlegel</surname><given-names>Friedrich</given-names></name><aff id="A133">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Pirard</surname><given-names>Marie France</given-names></name><aff id="A134">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Trung</surname><given-names>Nguyen</given-names></name><aff id="A135">Laboratoire National de Santé, Dudelange, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Jägi</surname><given-names>Philipp</given-names></name><aff id="A136">Laboratoire Réunis, Junglinster, Luxembourg;</aff></contrib><contrib contrib-type="author"><name><surname>Cauchie</surname><given-names>Henry-Michel</given-names></name><aff id="A137">Luxembourg Institute of Science and Technology, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Collart</surname><given-names>Delphine</given-names></name><aff id="A138">Luxembourg Institute of Science and Technology, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Ogorzaly</surname><given-names>Leslie</given-names></name><aff id="A139">Luxembourg Institute of Science and Technology, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Penny</surname><given-names>Christian</given-names></name><aff id="A140">Luxembourg Institute of Science and Technology, Luxembourg, Luxembourg</aff></contrib><contrib contrib-type="author"><name><surname>Walczak</surname><given-names>Cécile</given-names></name><aff id="A141">Luxembourg Institute of Science and Technology, Luxembourg, Luxembourg</aff></contrib></contrib-group></collab><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Krüger</surname><given-names>Rejko</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fagherazzi</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Ollert</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="A11">11</xref><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Hefeng</surname><given-names>Feng Q.</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Wilmes</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A13">13</xref></contrib></contrib-group><aff id="A1"><label>1</label>Systems Ecology group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg</aff><aff id="A2"><label>2</label>Clinical and Applied Virology, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg</aff><aff id="A3"><label>3</label>LCSB Operations, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg</aff><aff id="A4"><label>4</label>Scientific Central Services, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg</aff><aff id="A5"><label>5</label>Transversal Translation Medicine, Luxembourg Institute of Health, Strassen, Luxembourg</aff><aff id="A6"><label>6</label>Translational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg</aff><aff id="A7"><label>7</label>Translational Medicine Operations Hub, Luxembourg Institute of Health, Strassen, Luxembourg</aff><aff id="A8"><label>8</label>Bioinformatics Core, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg</aff><aff id="A9"><label>9</label>CON-VINCE consortium<sup>†</sup></aff><aff id="A10"><label>10</label>Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg</aff><aff id="A11"><label>11</label>Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg</aff><aff id="A12"><label>12</label>Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark</aff><aff id="A13"><label>13</label>Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, 6, avenue du Swing, Belvaux, L-4367, Luxembourg</aff><pub-date pub-type="nihms-submitted"><day>22</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>20</day><month>10</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Objectives</title><p id="P1">Infections with SARS-CoV-2 have a pronounced impact on the gastrointestinal tract and its resident microbiome. Clear differences between severe cases of infection and healthy individuals have been reported, including the loss of commensal taxa. We aimed to understand if microbiome alterations including functional shifts are unique to severe cases or a common effect of COVID-19.</p></sec><sec id="S2"><title>Design</title><p id="P2">We used high-resolution systematic multi-omic analyses to profile the gut microbiome in asymptomatic-to-moderate COVID-19 individuals compared to a control group.</p></sec><sec id="S3"><title>Results</title><p id="P3">We found a striking increase in the overall abundance and expression of both virulence factors and antimicrobial resistance genes in COVID-19. Importantly, these genes are encoded and expressed by commensal taxa from families such as Acidaminococcaceae and Erysipelatoclostridiaceae, which we found to be enriched in COVID-19 positive individuals. We also found an enrichment in the expression of a betaherpesvirus and rotavirus C genes in COVID-19 positive individuals compared to healthy controls.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">Our analyses identified an altered and increased infective competence of the gut microbiome in COVID-19 patients.</p></sec></abstract></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P5">Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic by the World Health Organisation (WHO). COVID-19 exhibits a high degree of clinical heterogeneity, ranging from asymptomatic to severe disease, and may be accompanied by a poor outcome and a relatively high mortality rate [<xref ref-type="bibr" rid="R1">1</xref>]. As of 17 October 2022, more than 621 million confirmed SARS-CoV-2 infections and 6.5 million COVID-19-related deaths have been reported [<xref ref-type="bibr" rid="R2">2</xref>]. Although COVID-19 is primarily considered a respiratory disease, it clinically often presents with general (fever, myalgia and/or fatigue) and respiratory symptoms (cough and/or dyspnea). Moreover, an emergence of new variants has led to the more frequent presentation of gastrointestinal symptoms (appetite loss, nausea, vomiting and diarrhoea) [<xref ref-type="bibr" rid="R3">3</xref>], indicating a potential involvement of the gastrointestinal tract in COVID-19. More specifically, SARS-CoV-2 has been shown to be able to infect and replicate in enterocytes <italic>in vitro</italic> [<xref ref-type="bibr" rid="R4">4</xref>]. In fact, viral RNA can be detected in faecal samples even after resolution of respiratory symptoms [<xref ref-type="bibr" rid="R5">5</xref>]. Additionally, SARS-CoV-2 infections are associated with alterations to the gut microbiome composition that persist for at least six months after the initial infection [<xref ref-type="bibr" rid="R6">6</xref>]. Thus, an imbalance in the gut microbiome can be linked to disease severity and increased concentrations of inflammatory markers, as well as an increased post-COVID-19 risk, understood as a wide range of symptoms persisting four or more weeks after the initial SARS-CoV-2 infection [<xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R8">8</xref>].</p><p id="P6">Stable ecosystems are important for colonisation resistance to pathogens [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R10">10</xref>]. As such, host and SARS-CoV-2-mediated immune dysregulation and dysbiosis may predispose patients to co-infections or secondary infections of the respiratory and gastrointestinal tracts. In addition, co-infecting microorganisms may alter the intensity of the host immune response [<xref ref-type="bibr" rid="R11">11</xref>], thus significantly influencing severity and outcome of the disease. For instance, co-infections with viruses (rhinovirus/enterovirus, respiratory syncytial virus, influenza virus, non–SARS-CoV-2 Coronavirus) [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref>], bacteria (<italic>Mycoplasma pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus</italic>) [<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref>], or fungi (<italic>Candida spp., Aspergillus spp.</italic>) [<xref ref-type="bibr" rid="R16">16</xref>] have been described among SARS-CoV-2 positive cases in different study set-ups. In particular, bacterial co-infections in hospitalised and intensive care unit patients with COVID-19 are associated with prolonged ventilation and an increased mortality rate [<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref>]. Furthermore, hospital-acquired infections with multi drug resistant (MDR) pathogens are also linked with increased mortality in COVID-19 patients [<xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref>]. These reports collectively suggest a clear shift in COVID-19 patients with respect to an increased abundance of pathogens and potential for harm. Moreover, these shifts may further manifest themselves in relation to the <italic>infective competence,</italic> i.e. the propensity for virulence and increased antibiotic resistance, in the gut microbiome as a consequence of an increased capacity to cause infections.</p><p id="P7">Major factors that contribute to the success of some of the pathogens highlighted above are virulence factors. Virulence factors including cell-surface structures, adhesins, siderophores, endo- and exotoxins enable pathogens to undergo quick adaptive shifts, invade and colonise host niches, as well as evade innate and adaptive immune mechanisms of the host, resulting in inflammation and clinical manifestations of the disease. Another factor facilitating colonisation of pathogens, through prevention of effective treatment, is antimicrobial resistance (AMR). Even though AMR is an ancient and natural phenomenon [<xref ref-type="bibr" rid="R22">22</xref>], it is usually linked to the human influence on the environment and the use of antibiotics. Overuse of antibiotics is hypothesised to also contribute to the broader problem of antimicrobial resistance [<xref ref-type="bibr" rid="R23">23</xref>]. Moreover, although not a virulence factor by itself, AMR shares common characteristics with virulence factors [<xref ref-type="bibr" rid="R24">24</xref>]. Specifically, AMR and virulence factors: 1) are necessary for the survival of pathogens under unfavourable conditions [<xref ref-type="bibr" rid="R25">25</xref>]; 2) can be transmitted between species by horizontal gene transfer [<xref ref-type="bibr" rid="R26">26</xref>]; and 3) both processes make use of similar systems, e.g. cell wall alterations, efflux pumps, porins and two-component systems to activate or repress expression of various genes [<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref>]. Thus, in response to host defence mechanisms and environmental challenges, communities of microorganisms, i.e. microbiomes, may alter their “<italic>infective competence</italic>”. The <italic>infective competence</italic> is defined as the ability of microorganisms to constantly adapt and evolve, utilising virulence factors and antimicrobial resistance mechanisms, resulting in increased survival, invasion, or growth. Importantly, the combination of host-driven factors, i.e. immune system-mediated effects and antimicrobial peptides, and unfavourable gastrointestinal conditions, e.g. low pH, disruption of the mucus layer, niche competition with other taxa, may confer transiently a selective advantage to a pathogenic lifestyle [<xref ref-type="bibr" rid="R29">29</xref>–<xref ref-type="bibr" rid="R32">32</xref>]. This may be reflected in the entire gut microbiome, possibly altering the <italic>infective competence</italic> of the endogenous taxa and subsequently giving rise to pathobiont-dominated communities.</p><p id="P8">Here, we addressed questions pertaining to the effect of SARS-CoV-2 infection on the endogenous gut microbiome in COVID-19 cases compared to healthy controls using systematic, high-resolution multi-omic data, including metagenomics and metatranscriptomics with a particular focus on virulence factors and antimicrobial resistance genes. We find that mild, i.e. asymptomatic-to-moderate, COVID-19 does not alter the overall composition of the gut microbiome, unlike the drastic microbiota changes reported previously in severe cases. Importantly, we find that a mild progression of COVID-19 affects the <italic>infective competence</italic> of gut microbiota, wherein taxa encode and express genes facilitating their survival and/or growth. We find specific families such as Acidaminococcaceae and Erysipelatoclostridiaceae to be encoding for and expressing virulence factors and ARGs, significantly more in individuals with COVID-19. Collectively our data also demonstrates a significantly higher <italic>infective competence</italic> of the endogenous microbiome, suggesting that infection with SARS-CoV-2 may mediate co-infections in the longer term.</p></sec><sec id="S6" sec-type="methods"><title>Methods</title><sec id="S7"><title>Ethics</title><p id="P9">The study was performed in accordance with the Good Clinical Practice and the Declaration of Helsinki. All participants in this study provided their written informed consent. The study was approved by the National Research Ethics Committee of Luxembourg (study number 202006/03). All biological samples and data were collected in the frame of Predi-COVID [<xref ref-type="bibr" rid="R33">33</xref>] and CON-VINCE studies. The studies were approved by the National Research Ethics Committee of Luxembourg (Predi-COVID study number 202003/07; CON-VINCE study number 202004/01).</p></sec><sec id="S8"><title>Cohort description and patient involvement</title><p id="P10">Between May and October 2020, stool samples were collected from 61 participants residing in Luxembourg with COVID-19 confirmed by positive SARS-CoV-2 RT-qPCR (<xref ref-type="supplementary-material" rid="SD1">Supp. Table 1</xref>) within the framework of the Predi-COVID study [<xref ref-type="bibr" rid="R33">33</xref>]. In order to be eligible to participate in the study, an individual must have met all the following criteria: (1) signed informed consent form; (2) individuals ≥ 18 years old with confirmed SARS-CoV-2 infection as determined by PCR, performed by one of the certified laboratories in Luxembourg; and (3) hospitalised or at home. In addition to the criteria specific to the Predi-COVID study, samples were excluded if antibiotic treatment was reported. From the individuals, relevant clinical data was collected using a modified version of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) case report form. The participants to be included in the study were classified using an adapted version of the National Institute of Healthy symptom severity scheme [<xref ref-type="bibr" rid="R34">34</xref>]. Subsequently, only asymptomatic to moderate symptoms were reported. Along with the samples from the COVID-19 confirmed participants, stool samples were collected from a group of 57 individuals who tested negative for SARS-CoV-2 by RT-qPCR, who were participants of the CON-VINCE study, a population-based cohort study which recruited a representative sample of the Luxembourg population, to serve as age-matched controls. Participation in the control group was excluded if matching any of the following criteria: (1) infection of SARS-CoV-2 prior to the study; (2) presence of fever and respiratory distress/cough not attributable to other known chronic disease; (3) usage of antibiotics up to three months prior to enrolment or first SARS-CoV-2 infection. The study design is presented in <xref ref-type="fig" rid="F1">Fig. 1</xref> while additional metadata are included in <xref ref-type="supplementary-material" rid="SD1">Supp. Table 1</xref>. Patients were not involved in setting the research questions or the outcome measures of this study.</p></sec><sec id="S9"><title>Sample collection, data processing and prediction of <italic>infective competence</italic></title><p id="P11">Stool samples were collected at home by individuals using DNA/RNA Shield Fecal Collection Tubes (Zymo Research), and samples and data were collected at the Integrated BioBank of Luxembourg. DNA and RNA were extracted from all collected stool samples and sequenced for metagenomic and metatranscriptomic analysis. Sequencing was performed at LCSB sequencing platform (RRID: SCR_021931) on NextSeq500 instrument using 2x150 bp read length. The data was analysed using the Integrated Meta-omic Pipeline (IMP; v3 - #b6f9da0e for preprocessing and #c04edbe for downstream analyses) [<xref ref-type="bibr" rid="R35">35</xref>]. MetaPhlAn3.1 (v3.1.0, database “mpa_v31_CHOCOPhlAn_201901”) was used for taxonomic profiling [<xref ref-type="bibr" rid="R36">36</xref>], while virulence factors and ARGs were identified using PathoFact (v1.0; #6fa64961). Detailed description of the DNA/RNA extractions, sequencing methodology, the analyses approaches, tools and their respective parameters are provided in the Supplementary Material.</p></sec></sec><sec id="S10" sec-type="results"><title>Results</title><sec id="S11"><title>Taxonomic and functional profiles indicate minimal changes in COVID-19</title><p id="P12">COVID-19 studies have reported an altered gut microbiota composition of hospitalised and critical COVID-19 patients. However, limited attention has been paid to milder forms of COVID-19. Thus, we assessed whether gut microbiota composition was altered in COVID-19 individuals compared to healthy controls. Overall, the gut microbiome compositions, based on the alpha- and beta-diversity metrics, of 61 COVID-19 and 57 individuals from the control group were similar (<xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="supplementary-material" rid="SD3">Supp. Fig. 1</xref>), with an increased abundance of species belonging to the Lachnospiraceae, Ruminococcaceae, Bacteroidaceae and Bifidobacteriaceae families in COVID-19 (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). We found specific taxonomic differences within the metagenomes, such as an increase in the abundance of AM10 47 (Firmicutes phylum), <italic>Prevotella sp.</italic> CAG 520, <italic>Prevotella stercorea</italic> and <italic>Roseburia sp.</italic> CAG 471 in the COVID-19 group (<xref ref-type="fig" rid="F2">Fig. 2b</xref>), along with a decrease in CAG 145 (Firmicutes phylum), <italic>Roseburia faecis</italic> and <italic>Turicibacter sanguinis</italic> (<xref ref-type="fig" rid="F2">Fig. 2c</xref>). Despite these taxonomic differences, we did not observe any significant changes in the overall functional profile of the microbiome between the COVID-19 and control groups.</p><p id="P13">In light of reports, indicating the potential co-infections with viruses along with SARS-CoV-2, we also assessed the virome within the COVID-19 patient and the control groups. We did not observe large differences between the groups. However, we found that genes associated with a specific betaherpesvirus and rotavirus were enriched (<italic>adj. p</italic> &lt; 0.05; One-Way ANOVA) in the COVID-19 group (<xref ref-type="supplementary-material" rid="SD2">Supp. Table 2</xref>).</p></sec><sec id="S12"><title>SARS-CoV-2 is associated with increased abundance and expression of virulence factors</title><p id="P14">SARS-CoV-2 infections have been suggested to predispose patients to co-infections or secondary infections of the respiratory and gastrointestinal tracts. Virulence factors in particular enable (pathogenic) microorganisms to colonise host niches and establish infections. We used PathoFact [<xref ref-type="bibr" rid="R37">37</xref>] to assess the prevalence of virulence factors in the co-assembled metagenomic and metatranscripomic data. PathoFact was designed to contextualise the genomic data and classify virulence factors and ARGs, allowing to assess the <italic>infective competence</italic> of taxa. To obtain a comprehensive overview of actual gene expression, we complemented metagenomic analyses with metatranscriptomic information conferring information regarding the transcription levels of identified virulence factors. Based on the metagenomic data, we found a significant increase (<italic>adj. p</italic> &lt; 0.05; Wilcoxon rank-sum test) in the overall abundance of virulence factors in the COVID-19 group compared to the control group (<xref ref-type="fig" rid="F3">Fig. 3a</xref>). The metatranscriptomic information further confirmed that these virulence factors demonstrated significantly increased expression levels (<italic>adj. p</italic> &lt; 0.05; Wilcoxon rank-sum test) in the COVID-19 group compared to the control group (<xref ref-type="fig" rid="F3">Fig. 3b</xref>).</p><p id="P15">To link the prevalence and expression of the identified virulence factors to the taxa within the microbial community, we reconstructed metagenome-assembled genomes (MAGs) and further leveraged the iterative workflow of the integrated meta-omic pipeline (IMP) [<xref ref-type="bibr" rid="R35">35</xref>]. Overall we found a significant increase in encoded and expressed virulence factors between the COVID-19 and control groups (<italic>adj. p</italic> &lt; 0.05; Wilcoxon rank-sum test). Our analyses further linked families such as Acidaminococcaceae, Erysipelatoclostridiaceae and Erysipelotrichaceae with increased expression of virulence factors in the COVID-19 group (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). Interestingly, the control group exhibited higher gene abundances and expression of virulence factors only in the Dialisteraceae family. Furthermore, we found that some families (Acutalibacteraceae, Coriobacteriaceae, Lachnospiraceae and Ruminococcaceae) demonstrated an increased expression of virulence factors in the COVID-19 group (<xref ref-type="fig" rid="F3">Fig. 3d</xref>; <italic>adj. p</italic> &lt; 0.05; Wilcoxon rank-sum test), although their respective gene abundances were not different from those found in the control group.</p></sec><sec id="S13"><title>Expression of antimicrobial resistance increases together with virulence factors</title><p id="P16">While co-infections or secondary infections in COVID-19 may exacerbate the disease, the presence of ARGs may limit treatment options. Since the overall abundance and expression of virulence factors was increased in COVID-19 individuals, we assessed the antimicrobial resistance profile of the microbial community in the COVID-19 and control groups. Specifically, using PathoFact, we characterised the prevalence and expression of ARGs (22 categories). While we did not find any significant differences in the overall gene abundances of all ARGs contributing to the resistome, we observed a significant increase (<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test) in ARG expression levels between COVID-19 and the control groups (<xref ref-type="fig" rid="F4">Fig. 4a</xref>). Importantly, when investigating individual AMR categories, we found that beta-lactam and peptide resistance were both significantly higher in terms of gene abundance and also more highly expressed within the COVID-19 group (<xref ref-type="fig" rid="F4">Fig. 4b</xref>; <italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test). In addition, we observed that the expression of multidrug resistance was enriched (<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test) in the COVID-19 group, while macrolides, lincosamides and streptogramins (MLS) resistance also exhibited a higher gene abundance in the same group (<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test).</p><p id="P17">As described above, we leveraged the MAGs to correlate the differentially abundant and expressed ARGs to the microbial community. In line with our observations with the virulence factors, we found a significant increase (<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test) in ARGs encoded and expressed by the Acidaminococcaceae and Erysipelatoclostridiaceae in the COVID-19 group (<xref ref-type="fig" rid="F5">Fig. 5a-b</xref>). Furthermore, an additional family, i.e. Tannerellaceae was also associated with increased abundance and expression of ARGs in the COVID-19 group (<xref ref-type="fig" rid="F5">Fig. 5a-b</xref>). Specifically, in relation to the above reported AMR categories we identified a significant increase in multidrug resistance encoded and expressed by all three of these taxonomic families. In addition, the Acidaminococcaceae also were found to encode a significant increase in ARGs contributing to peptide resistance. Interestingly, we found that several other taxonomic families were also associated with increased ARG expression in the COVID-19 group (<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test), although their gene abundances did not demonstrate any significant differences (<xref ref-type="fig" rid="F5">Fig. 5b</xref>). These included Barnesiellaceae, Coriobacteriaceae, Lachnospiraceae and Rikenellaceae.</p></sec><sec id="S14"><title><italic>Infective competence</italic> of the gut microbiome</title><p id="P18">Our analyses collectively indicated that both virulence factors and ARGs were enriched in abundance and expression in the COVID-19 group. Specifically, we found that the abundances of ARGs were correlated with those of the virulence factors (<xref ref-type="fig" rid="F6">Fig. 6a</xref>, R=0.52 and <italic>p</italic> &lt; 0.01; Spearman’s correlation). Complementing this observation, we found that the expression profiles of ARGs and virulence factors also correlated with each other (<xref ref-type="fig" rid="F6">Fig. 6b</xref>, R=0.46 and <italic>p</italic> &lt; 0.01; Spearman’s correlation) suggesting a higher propensity for infectious capacity. To further characterise the <italic>infective competence</italic> of the various taxa within the gut microbiome, we estimated the log2 fold-change of the abundance and expression of virulence factors and ARGs across taxonomic families found in the COVID-19 group and the control group. We found that ~62% (21/34) of the families had a higher <italic>infective competence</italic> and were enriched in abundance and expression within the COVID-19 group, whereas only ~9% (3/34) of the families showed increased <italic>infective competence</italic> in the control group (<xref ref-type="fig" rid="F6">Fig. 6c</xref>). In particular, these analyses highlighted the Acidaminococcaceae and Erysipelatoclostridiaceae families<italic>,</italic> in line with our earlier observations, suggesting a higher <italic>infective competence</italic>, where the abundances and expression levels of the virulence factors and ARGs were significantly higher in COVID-19 compared to the control group (<italic>p</italic> &lt; 0.05; Two-way ANOVA). In the control group, Dialisteraceae, which was also observed earlier, showed increased <italic>infective competence</italic> (<xref ref-type="fig" rid="F6">Fig. 6c</xref>). Collectively, our data suggests that the <italic>infective competence</italic> of taxa found in the COVID-19 group is increased compared to controls.</p></sec></sec><sec id="S15" sec-type="discussion"><title>Discussion</title><p id="P19">COVID-19 has become a common condition for which the manifold effects however remain a challenge [<xref ref-type="bibr" rid="R38">38</xref>]. Since the onset of the pandemic, the presentation of gastrointestinal symptoms has indicated the involvement of the gastrointestinal tract in COVID-19 [<xref ref-type="bibr" rid="R7">7</xref>]. As we uncover and understand the potential effects of COVID-19 in humans, it is important to also elucidate the concomitant consequences of the disease on the gut microbiome. To this end, several studies have focused on the drastic shifts in the microbiome of COVID-19 patients with severe symptoms. These include changes in diversity [<xref ref-type="bibr" rid="R39">39</xref>] including stark enrichments and/or loss of specific taxa [<xref ref-type="bibr" rid="R40">40</xref>]. Several Studies have focused on differences in the gut microbiome between patients with severe COVID-19 and controls [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R42">42</xref>]. Though these findings are essential, the effect on the larger population, wherein the infection is asymptomatic-to-moderate, is not readily represented. To address this particular gap in knowledge, we focused on the effect of COVID-19 in cases with asymptomatic-to-moderate symptoms in comparison to controls. Interestingly, we found that the diversity and overall shifts in community composition, highlighted in previous reports between severe and control patients [<xref ref-type="bibr" rid="R39">39</xref>], did not manifest themselves when comparing asymptomatic-to-moderate cases to the control group of individuals. However, this was associated with an increased abundances of specific taxa such as <italic>Prevotella</italic> spp., AM10 and CAG145 (Firmicutes phylum), <italic>Roseburia</italic> spp. and a <italic>Turicibacter</italic> spp. in the COVID-19 group. This is in contrast to existing reports [<xref ref-type="bibr" rid="R40">40</xref>,<xref ref-type="bibr" rid="R43">43</xref>], suggesting the loss of beneficial taxa such as <italic>Faecalibacterium</italic>, <italic>Bifidobacterium</italic> and <italic>Roseburia</italic> in the context of COVID-19. Since our study did not include patients with severe COVID-19 or those that were hospitalised, it is likely that the lower disease severity does not lead to significant changes in the abundance of beneficial commensals. Along similar lines, major differences in the virome profile of the COVID-19 group in our study were not observed when compared to the control group. Nevertheless, and importantly, we found that genes associated with rotavirus C were increasingly expressed in the COVID-19 group, despite no differences in overall abundance of this virus between the patient groups. Rotavirus is a known enteric pathogen causing gastroenteritis in the paediatric population, however, their capacity to cause infections in adults is underappreciated and poorly characterised due to only mild symptoms including nausea, headaches and diarrhoea [<xref ref-type="bibr" rid="R44">44</xref>]. Importantly, at the time of writing only one report by Wang <italic>et al.</italic> [<xref ref-type="bibr" rid="R45">45</xref>], indicated the possibility of increased rotavirus A-mediated enteric infections in COVID-19 patients. These findings are intriguing given the propensity for COVID-19 patients to suffer from enteric symptoms [<xref ref-type="bibr" rid="R3">3</xref>], including nausea [<xref ref-type="bibr" rid="R46">46</xref>] and diarrhoea [<xref ref-type="bibr" rid="R47">47</xref>]. Whether the rotavirus, especially in adults, is associated with COVID-19 gastrointestinal symptoms, or the enteric effects exacerbate the expression of rotavirus C-associated genes is still unknown and will have to be investigated in dedicated follow-up studies.</p><p id="P20">In line with the above observations, early in the pandemic, the role of COVID-19 in enhancing co-infections was documented extensively [<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R48">48</xref>,<xref ref-type="bibr" rid="R49">49</xref>]. This is not limited to mucormycosis [<xref ref-type="bibr" rid="R50">50</xref>] which was amplified in certain parts of the world, but also bacterial and viral co-infections that were reported in severe COVID-19 patients [<xref ref-type="bibr" rid="R45">45</xref>]. Despite these observations and case studies, the effect of COVID-19 on the <italic>infective competence</italic> of the existing and endogenous microbiota has never been characterised. Our findings, therefore, bridge an important and broad chasm in knowledge, suggesting that COVID-19-mediated shifts may lead to higher microbiome-linked burden with potentially manifold effects. Importantly, we not only found an increased abundance in virulence factors in the COVID-19 group, but also a concomitant increase in expression of genes associated with virulence. Such infection-linked shifts have not been reported beforehand and may be used to monitor and understand potential future infections, in the context of COVID-19-mediated effects. Simultaneously, we found that these virulence factors were associated with taxa from families such as Acidaminococcaceae, Erysipelatoclostridiaceae and Erysipelotrichaceae. Though Acidaminococcus was recently reported to be associated with a disease-related group in a large-scale meta-analysis [<xref ref-type="bibr" rid="R51">51</xref>], the exact role of Acidaminococcaceae in virulence is undocumented. Members of the Erysipelatoclostridiaceae family are typically seen as typical members of the microbiome, however in specific cases species such as <italic>Erysipelatoclostrium ramosum</italic> have been associated with systemic infection and systemic inflammatory response syndrome [<xref ref-type="bibr" rid="R52">52</xref>], while Erysipelotrichaceae have been positively correlated with colorectal cancer [<xref ref-type="bibr" rid="R53">53</xref>]. Our observations, especially the increased expression of virulence factor genes associated with these taxa, may pave the way in future explorations to serve as indicators of diseases. Importantly, it is still unclear whether the enriched <italic>infective competence</italic> is a COVID-19-specific hallmark or one found in all infections. For example, it has previously been hypothesised that selection of pathobionts result from inflammatory responses and/or a dysregulation of the tolerant immune system [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R55">55</xref>]. Future studies will need to address the extent to which various underlying factors such as a dysbiotic microbiome and an impaired immune system affect the <italic>infective competence</italic> of the gut microbiome.</p><p id="P21">Another important aspect of COVID-19, in particular early on in the pandemic, was the overuse and misuse of antibiotics for treating SARS-CoV-2 [<xref ref-type="bibr" rid="R56">56</xref>,<xref ref-type="bibr" rid="R57">57</xref>] which was also associated with the potential increase of AMR [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R58">58</xref>]. Recent studies have reported on the higher incidence of AMR [<xref ref-type="bibr" rid="R58">58</xref>] and increased ARGs in COVID-19 patients [<xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R60">60</xref>]. However, these reports either refer to patients who were administered antibiotics [<xref ref-type="bibr" rid="R59">59</xref>] or include a meta-analyses observing datasets which were generated pre- and post-pandemic, specifically associated with travel [<xref ref-type="bibr" rid="R61">61</xref>], or limit characterisation of antibiotic-mediated differences at a broad and low-resolution [<xref ref-type="bibr" rid="R62">62</xref>]. In contrast to these studies, antibiotic usage was a clear exclusion criterion in our study where individuals included were not administered any antibiotics three months prior to sampling. To our knowledge, our findings are the first report to systematically analyse the resistome of COVID-19 and control individuals and importantly to demonstrate that several of these ARGs are indeed expressed significantly higher in the COVID-19 group compared to the control group, regardless of antibiotic treatment. We observe that resistance genes include MLS, multidrug and peptides, resistance classes where treatments of resistant bacteria are known to be inherently challenging with conventional antibiotics [<xref ref-type="bibr" rid="R63">63</xref>,<xref ref-type="bibr" rid="R64">64</xref>]. Strikingly, we found that the increased ARG expression in the COVID-19 group was further associated with the same taxa encoding and expressing virulence factors. This suggests that combinatorial effects of virulence factors and ARGs may exacerbate the <italic>infective competence</italic> of these taxa. This is further supported by our analysis identifying that taxa from the Acidaminococcaceae and Erysipelatoclostridiaceae families demonstrated a predicted higher <italic>infective competence</italic> in the COVID-19 group.</p><p id="P22">Our findings suggest that it is imperative to elucidate all the implications of SARS-CoV-2 infection, especially its effect on the gut microbiome community and functions. Although other studies have involved the severe cases of COVID-19 [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R65">65</xref>,<xref ref-type="bibr" rid="R66">66</xref>], none of these studies include both metagenomic and metatranscriptomic sequencing data. We found that the virulence factors and antimicrobial resistance genes were indeed expressed in higher levels in the COVID-19 group compared to the controls. These key findings would have not been possible by only focussing on metagenomic data. Our collective findings, indicating the enriched abundance and expression of both virulence factors and ARGs, suggest that COVID-19 may yet have unknown effects that may come to light in the longer term including the shaping of the microbiome across the population. Moreover, we find that none of the commonly reported pathogens <italic>(Salmonella</italic>, <italic>Shigella</italic>,<italic>Klebsiella</italic> etc.) are enriched in the COVID-19 group in our study. In contrast, we find changes in <italic>Prevotella</italic> spp, AM10 and CAG145 (Firmicutes phylum), <italic>Roseburia</italic> spp and a <italic>Turicibacter</italic> spp. Therefore, it will be critically important to evaluate and further validate the effects of COVID-19 on the gut microbiome also in relation to infections by other viral and other pathogens. In particular, it remains unclear at this time, whether infections with other viruses, known to cause respiratory and gastrointestinal distress, e.g. Adenoviruses, respiratory syncytial virus (RSV), influenza viruses, norovirus, would lead to similar community and functional changes within the gut microbiome. Overall, it must be reiterated that pandemic preparedness coupled to the monitoring of virulence factors in tandem with antibiotic stewardship may be essential components for future strategies to mitigate the longer-term effects of COVID-19 and possibly other viral infections.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Table 1</label><media xlink:href="EMS156047-supplement-Supplementary_Table_1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d98aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Table 2</label><media xlink:href="EMS156047-supplement-Supplementary_Table_2.csv" mimetype="text" mime-subtype="csv; charset=utf-8" id="d98aAdEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Supplementary Figure</label><media xlink:href="EMS156047-supplement-Supplementary_Figure.pdf" mimetype="text" mime-subtype="csv; charset=utf-8" id="d98aAdEdB" position="anchor"/></supplementary-material></sec></body><back><ack id="S16"><title>Acknowledgements</title><p>We acknowledge the active involvement of all the participants of the Predi-COVID and CONVINCE cohorts. We are also thankful for the support of the cohort recruitment and processing teams. We also acknowledge Prof. Laetitia Huiart for her efforts in initiating the Predi-COVID cohort and Aurélie Sausy, Sophie Mériaux, and Jean-Yves Servais for their technical help. The Predi-COVID study is supported by the Luxembourg National Research Fund (FNR: 14716273), the Fondation André Losch, and the European Regional Development Fund (FEDER, no. 2018-04-026-21). F.Q.H. was partially supported by FNR AFR-RIKEN bilateral program (TregBAR, 11228353, F.Q.H. and M.O.) and PRIDE programme (11012546/NEXTIMMUNE and 10907093/CRITICS). The CON-VINCE study is supported by the Fonds National de la Recherche (FNR: 14716281/CON-VINCE/Kruger) and the André Losch Foundation. P.W. acknowledges funding from the European Research Council under the European Union’s Horizon 2020 research and innovation program (no. 863664). LdN, PM and PW are supported by the Luxembourg National Research Fund (FNR; PRIDE17/11823097) awarded to PW. We would also like to acknowledge the following funding instruments: FNR: COVID-19/2020-1/14719552/FunBiome. The work was further supported by the Luxembourg Government through the CoVaLux programme. This research has also been supported by the Swiss National Science Foundation (CRSII5_180241) supporting SBB. We would like to thank Susana Martinez Arbas for the initial support during data preprocessing. The authors are also grateful to the Luxembourg Ministry of Higher Education and Research and the Ministry of Health for funding the intervention. The computational analyses were performed at the HPC facilities at the University of Luxembourg (<ext-link ext-link-type="uri" xlink:href="https://hpc.uni.lu">https://hpc.uni.lu</ext-link>) [<xref ref-type="bibr" rid="R67">67</xref>].</p></ack><sec id="S17" sec-type="data-availability"><title>Code and data availability</title><p id="P23">All code used for metagenomic and metatranscriptomic data analysis can be found in the following repositories: <ext-link ext-link-type="uri" xlink:href="https://gitlab.lcsb.uni.lu/ESB/co-infectomics">https://gitlab.lcsb.uni.lu/ESB/co-infectomics</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://gitlab.lcsb.uni.lu/laura.denies/co-infectomics_r_analysis">https://gitlab.lcsb.uni.lu/laura.denies/co-infectomics_r_analysis</ext-link>. Reads filtered against the human genome (hg38), were submitted to the Sequence Read Archive hosted under accession PRJNA890008. Metadata is included in <xref ref-type="supplementary-material" rid="SD1">Supp. Table 1</xref> and all other data can be found on Zenodo (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7192682">https://doi.org/10.5281/zenodo.7192682</ext-link>).</p></sec><fn-group><title>Declarations</title><fn id="FN1" fn-type="con"><p id="P24"><bold>Authors’ contributions</bold></p><p id="P25">The authors are solely responsible for all aspects of this article including the research, the interpretation, and the writing thereof. PW, LD, CMG, SBB and CCL conceived the study, while LdN, VG and SBB performed data analysis, data interpretation and in conjunction with MD wrote the manuscript. CS, FH, and PM contributed to critical experiments and analyses. RH, JH and PCL were instrumental in sequencing the samples. GF, MO, JVF, TM, ES, MPOS, SG, VS were responsible for the data and sample collection of the Predi-COVID or CON-VINCE cohorts. All authors were involved in writing and approval of the manuscript.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><etal/></person-group><article-title>The immunology and immunopathology of COVID-19</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>1122</fpage><lpage>7</lpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="web"><source>WHO Coronavirus (COVID-19) dashboard</source><date-in-citation>accessed 29 Sep 2022</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link></comment></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Elbéji</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long COVID Symptomatology After 12 Months and Its Impact on Quality of Life According to Initial Coronavirus Disease 2019 Disease Severity</article-title><source>Open Forum Infect Dis</source><year>2022</year><volume>9</volume><elocation-id>ofac397</elocation-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Beumer</surname><given-names>J</given-names></name><name><surname>van der Vaart</surname><given-names>J</given-names></name><etal/></person-group><article-title>SARS-CoV-2 productively infects human gut enterocytes</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>50</fpage><lpage>4</lpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prolonged presence of SARS-CoV-2 viral RNA in faecal samples</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><fpage>434</fpage><lpage>5</lpage></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Six-month follow-up of gut microbiota richness in patients with COVID-19</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>222</fpage><lpage>5</lpage></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeoh</surname><given-names>YK</given-names></name><name><surname>Zuo</surname><given-names>T</given-names></name><name><surname>Lui</surname><given-names>GC-Y</given-names></name><etal/></person-group><article-title>Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19</article-title><source>Gut</source><year>2021</year><volume>70</volume><fpage>698</fpage><lpage>706</lpage></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>JB</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><etal/></person-group><article-title>A clinical case definition of post-COVID-19 condition by a Delphi consensus</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><fpage>e102</fpage><lpage>7</lpage></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffie</surname><given-names>CG</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Microbiota-mediated colonization resistance against intestinal pathogens</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><fpage>790</fpage><lpage>801</lpage></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorbara</surname><given-names>MT</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them</article-title><source>Mucosal Immunol</source><year>2019</year><volume>12</volume><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devi</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Chattopadhyay</surname><given-names>P</given-names></name><etal/></person-group><article-title>Co-infections as Modulators of Disease Outcome: Minor Players or Major Players?</article-title><source>Front Microbiol</source><year>2021</year><volume>12</volume><elocation-id>664386</elocation-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><name><surname>Pinsky</surname><given-names>B</given-names></name><etal/></person-group><article-title>Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>2085</fpage><lpage>6</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Deveson</surname><given-names>IW</given-names></name><name><surname>Pang</surname><given-names>CNI</given-names></name><etal/></person-group><article-title>Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome capture sequencing</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>3934</fpage></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lansbury</surname><given-names>L</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Baskaran</surname><given-names>V</given-names></name><etal/></person-group><article-title>Co-infections in people with COVID-19: a systematic review and meta-analysis</article-title><source>J Infect</source><year>2020</year><volume>81</volume><fpage>266</fpage><lpage>75</lpage></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Vidal</surname><given-names>C</given-names></name><name><surname>Sanjuan</surname><given-names>G</given-names></name><name><surname>Moreno-García</surname><given-names>E</given-names></name><etal/></person-group><article-title>Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study</article-title><source>Clin Microbiol Infect</source><year>2021</year><volume>27</volume><fpage>83</fpage><lpage>8</lpage></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutsaert</surname><given-names>L</given-names></name><name><surname>Steinfort</surname><given-names>N</given-names></name><name><surname>Van Hunsel</surname><given-names>T</given-names></name><etal/></person-group><article-title>COVID-19-associated invasive pulmonary aspergillosis</article-title><source>Ann Intensive Care</source><year>2020</year><volume>10</volume><fpage>71</fpage></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouzé</surname><given-names>A</given-names></name><name><surname>Martin-Loeches</surname><given-names>I</given-names></name><name><surname>Povoa</surname><given-names>P</given-names></name><etal/></person-group><article-title>Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study</article-title><source>Intensive Care Med</source><year>2021</year><volume>47</volume><fpage>188</fpage><lpage>98</lpage></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buehler</surname><given-names>PK</given-names></name><name><surname>Zinkernagel</surname><given-names>AS</given-names></name><name><surname>Hofmaenner</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients</article-title><source>Cell Reports Medicine</source><year>2021</year><volume>2</volume><elocation-id>100229</elocation-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>DL</given-names></name><name><surname>Lima</surname><given-names>CM</given-names></name><name><surname>Magalhães</surname><given-names>VCR</given-names></name><etal/></person-group><article-title>Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients</article-title><source>J Hosp Infect</source><year>2021</year><volume>113</volume><fpage>145</fpage><lpage>54</lpage></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoso</surname><given-names>P</given-names></name><name><surname>Sung</surname><given-names>M</given-names></name><name><surname>Hartantri</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MDR Pathogens Organisms as Risk Factor of Mortality in Secondary Pulmonary Bacterial Infections Among COVID-19 Patients: Observational Studies in Two Referral Hospitals in West Java, Indonesia</article-title><source>Int J Gen Med</source><year>2022</year><volume>I5</volume><fpage>4741</fpage><lpage>51</lpage></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Scaravilli</surname><given-names>V</given-names></name><name><surname>Mangioni</surname><given-names>D</given-names></name><etal/></person-group><article-title>Hospital-Acquired Infections in Critically Ill Patients With COVID-19</article-title><source>Chest</source><year>2021</year><volume>160</volume><fpage>454</fpage><lpage>65</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Costa</surname><given-names>VM</given-names></name><name><surname>King</surname><given-names>CE</given-names></name><name><surname>Kalan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Antibiotic resistance is ancient</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>457</fpage><lpage>61</lpage></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelfrene</surname><given-names>E</given-names></name><name><surname>Botgros</surname><given-names>R</given-names></name><name><surname>Cavaleri</surname><given-names>M</given-names></name></person-group><article-title>Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?</article-title><source>Antimicrob Resist Infect Control</source><year>2021</year><volume>10</volume><fpage>21</fpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beceiro</surname><given-names>A</given-names></name><name><surname>Tomás</surname><given-names>M</given-names></name><name><surname>Bou</surname><given-names>G</given-names></name></person-group><article-title>Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?</article-title><source>Clin Microbiol Rev</source><year>2013</year><volume>26</volume><fpage>185</fpage><lpage>230</lpage></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>JL</given-names></name><name><surname>Baquero</surname><given-names>F</given-names></name></person-group><article-title>Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance</article-title><source>Clin Microbiol Rev</source><year>2002</year><volume>I5</volume><fpage>647</fpage><lpage>79</lpage></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrus</surname><given-names>V</given-names></name><name><surname>Waldor</surname><given-names>MK</given-names></name></person-group><article-title>Shaping bacterial genomes with integrative and conjugative elements</article-title><source>Res Microbiol</source><year>2004</year><volume>155</volume><fpage>376</fpage><lpage>86</lpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosengren</surname><given-names>LB</given-names></name><name><surname>Waldner</surname><given-names>CL</given-names></name><name><surname>Reid-Smith</surname><given-names>RJ</given-names></name></person-group><article-title>Associations between antimicrobial resistance phenotypes, antimicrobial resistance genes, and virulence genes of fecal Escherichia coli isolates from healthy grow-finish pigs</article-title><source>Appl Environ Microbiol</source><year>2009</year><volume>75</volume><fpage>1373</fpage><lpage>80</lpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybak</surname><given-names>B</given-names></name><name><surname>Krawczyk</surname><given-names>B</given-names></name><name><surname>Furmanek-Blaszk</surname><given-names>B</given-names></name><etal/></person-group><article-title>Antibiotic resistance, virulence, and phylogenetic analysis of Escherichia coli strains isolated from free-living birds in human habitats</article-title><source>PLoS One</source><year>2022</year><volume>l7</volume><elocation-id>e0262236</elocation-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>NF</given-names></name><name><surname>Wickham</surname><given-names>ME</given-names></name><name><surname>Coombes</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Crossing the line: selection and evolution of virulence traits</article-title><source>PLoS Pathog</source><year>2006</year><volume>2</volume><fpage>e42</fpage></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masri</surname><given-names>L</given-names></name><name><surname>Branca</surname><given-names>A</given-names></name><name><surname>Sheppard</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Host-Pathogen Coevolution: The Selective Advantage of Bacillus thuringiensis Virulence and Its Cry Toxin Genes</article-title><source>PLoS Biol</source><year>2015</year><volume>l3</volume><elocation-id>e1002169</elocation-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Resident bacteria contribute to opportunistic infections of the respiratory tract</article-title><source>PLoS Pathog</source><year>2021</year><volume>l7</volume><elocation-id>e1009436</elocation-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>JL</given-names></name></person-group><article-title>Short-sighted evolution of bacterial opportunistic pathogens with an environmental origin</article-title><source>Front Microbiol</source><year>2014</year><volume>5</volume><fpage>239</fpage></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagherazzi</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Betsou</surname><given-names>F</given-names></name><etal/></person-group><article-title>Protocol for a prospective, longitudinal cohort of people with COVID-19 and their household members to study factors associated with disease severity: the Predi-COVID study</article-title><source>BMJ Open</source><year>2020</year><volume>IO</volume><elocation-id>e041834</elocation-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="web"><collab>Clinical spectrum</collab><source>COVID-19 Treatment Guidelines</source><date-in-citation>accessed 18 Oct 2022</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/">https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</ext-link></comment></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanasamy</surname><given-names>S</given-names></name><name><surname>Jarosz</surname><given-names>Y</given-names></name><name><surname>Muller</surname><given-names>EEL</given-names></name><etal/></person-group><article-title>IMP: a pipeline for reproducible reference independent integrated metagenomic and metatranscriptomic analyses</article-title><source>Genome Biol</source><year>2016</year><volume>I7</volume><fpage>260</fpage></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beghini</surname><given-names>F</given-names></name><name><surname>McIver</surname><given-names>LJ</given-names></name><name><surname>Blanco-Míguez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Integrating taxonomic, functional, and strainlevel profiling of diverse microbial communities with bioBakery 3</article-title><source>Elife</source><year>2021</year><volume>10</volume><pub-id pub-id-type="doi">10.7554/eLife.65088</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Nies</surname><given-names>L</given-names></name><name><surname>Lopes</surname><given-names>S</given-names></name><name><surname>Busi</surname><given-names>SB</given-names></name><etal/></person-group><article-title>PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data</article-title><source>Microbiome</source><year>2021</year><volume>9</volume><fpage>49</fpage></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Ramirez</surname><given-names>DC</given-names></name><name><surname>Normand</surname><given-names>K</given-names></name><name><surname>Zhaoyun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Long-Term Impact of COVID-19: A Systematic Review of the Literature and Meta-Analysis</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><pub-id pub-id-type="doi">10.3390/biomedicines9080900</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><etal/></person-group><article-title>The human microbiome and COVID-19: A systematic review</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><elocation-id>e0253293</elocation-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazan</surname><given-names>S</given-names></name><name><surname>Stollman</surname><given-names>N</given-names></name><name><surname>Bozkurt</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity</article-title><source>BMJ Open Gastroenterol</source><year>2022</year><volume>9</volume><pub-id pub-id-type="doi">10.1136/bmjgast-2022-000871</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Masuoka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human gut microbiota and its metabolites impact immune responses in COVID-19 and its complications</article-title><source>Gastroenterology</source><date-in-citation>Published Online First: 22 September 2022</date-in-citation><pub-id pub-id-type="doi">10.1053/j.gastro.2022.09.024</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lymberopoulos</surname><given-names>E</given-names></name><name><surname>Gentili</surname><given-names>GI</given-names></name><name><surname>Budhdeo</surname><given-names>S</given-names></name><etal/></person-group><article-title>COVID-19 severity is associated with population-level gut microbiome variations</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><elocation-id>963338</elocation-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Lui</surname><given-names>GCY</given-names></name><etal/></person-group><article-title>Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization</article-title><source>Gastroenterology</source><year>2020</year><volume>159</volume><fpage>944</fpage><lpage>55</lpage><elocation-id>e8</elocation-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Weber</surname><given-names>SG</given-names></name></person-group><article-title>Rotavirus infection in adults</article-title><source>Lancet Infect Dis</source><year>2004</year><volume>4</volume><fpage>91</fpage><lpage>9</lpage></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L-P</given-names></name><name><surname>Han</surname><given-names>J-Y</given-names></name><name><surname>Zhou</surname><given-names>S-X</given-names></name><etal/></person-group><article-title>The changing pattern of enteric pathogen infections in China during the COVID-19 pandemic: a nation-wide observational study</article-title><source>Lancet Reg Health West Pac</source><year>2021</year><volume>16</volume><elocation-id>100268</elocation-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Lui</surname><given-names>RN</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name></person-group><article-title>Covid-19 and the digestive system</article-title><source>J Gastroenterol Hepatol</source><year>2020</year><volume>35</volume><fpage>744</fpage><lpage>8</lpage></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Amico</surname><given-names>F</given-names></name><name><surname>Baumgart</surname><given-names>DC</given-names></name><name><surname>Danese</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management</article-title><source>Clin Gastroenterol Hepatol</source><year>2020</year><volume>18</volume><fpage>1663</fpage><lpage>72</lpage></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>VM</given-names></name><name><surname>Gandhi</surname><given-names>TN</given-names></name><name><surname>Petty</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><fpage>e533</fpage><lpage>41</lpage></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teklemariam</surname><given-names>AD</given-names></name><name><surname>Hashem</surname><given-names>AM</given-names></name><name><surname>Saber</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Bacterial co-infections and antimicrobial resistance associated with the Coronavirus Disease 2019 infection</article-title><source>Biotechnol Genet Eng Rev</source><year>2022</year><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napkins</surname><given-names>D</given-names></name><name><surname>Grand</surname><given-names>R</given-names></name></person-group><article-title>Mucormycosis. The Black Fungus: 2021 Everything You Need to Know About Black Fungus Symptoms, Risks, Facts and Gossip</article-title><source>Amazon Digital Services LLC - KDP Print US</source><year>2021</year></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manor</surname><given-names>O</given-names></name><name><surname>Dai</surname><given-names>CL</given-names></name><name><surname>Kornilov</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Health and disease markers correlate with gut microbiome composition across thousands of people</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>5206</fpage></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milosavljevic</surname><given-names>MN</given-names></name><name><surname>Kostic</surname><given-names>M</given-names></name><name><surname>Milovanovic</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antimicrobial treatment of Erysipelatoclostridium ramosum invasive infections: a systematic review</article-title><source>Rev Inst Med Trop Sao Paulo</source><year>2021</year><volume>63</volume><fpage>e30</fpage></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candela</surname><given-names>M</given-names></name><name><surname>Turroni</surname><given-names>S</given-names></name><name><surname>Biagi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inflammation and colorectal cancer, when microbiotahost mutualism breaks</article-title><source>World J Gastroenterol</source><year>2014</year><volume>2O</volume><fpage>908</fpage><lpage>22</lpage></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>H</given-names></name><name><surname>Sharma</surname><given-names>KK</given-names></name><name><surname>Tuovinen</surname><given-names>OH</given-names></name><etal/></person-group><article-title>Pathobionts: mechanisms of survival, expansion, and interaction with host with a focus on Clostridioides difficile</article-title><source>Gut Microbes</source><year>2021</year><volume>13</volume><elocation-id>1979882</elocation-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jochum</surname><given-names>L</given-names></name><name><surname>Stecher</surname><given-names>B</given-names></name></person-group><article-title>Label or Concept - What Is a Pathobiont?</article-title><source>Trends Microbiol</source><year>2020</year><volume>28</volume><fpage>789</fpage><lpage>92</lpage></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chedid</surname><given-names>M</given-names></name><name><surname>Waked</surname><given-names>R</given-names></name><name><surname>Haddad</surname><given-names>E</given-names></name><etal/></person-group><article-title>Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy</article-title><source>J Infect Public Health</source><year>2021</year><volume>14</volume><fpage>570</fpage><lpage>6</lpage></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Guerra</surname><given-names>BA</given-names></name><name><surname>Gonzalez-Lara</surname><given-names>MF</given-names></name><name><surname>de-Leon-Cividanes</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic</article-title><source>Antibiotics (Basel)</source><year>2021</year><volume>10</volume><pub-id pub-id-type="doi">10.3390/antibiotics10020182</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariyawasam</surname><given-names>RM</given-names></name><name><surname>Julien</surname><given-names>DA</given-names></name><name><surname>Jelinski</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021)</article-title><source>Antimicrob Resist Infect Control</source><year>2022</year><volume>11</volume><fpage>45</fpage></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Alterations of fecal antibiotic resistome in COVID-19 patients after empirical antibiotic exposure</article-title><source>Int J Hyg Environ Health</source><year>2022</year><volume>240</volume><elocation-id>113882</elocation-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venzon</surname><given-names>M</given-names></name><name><surname>Bernard-Raichon</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocation</article-title><source>bioRxiv</source><date-in-citation>Published Online First: 2 March 2022</date-in-citation><pub-id pub-id-type="doi">10.1101/2021.07.15.452246</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changes</article-title><source>J Travel Med</source><year>2021</year><volume>28</volume><pub-id pub-id-type="doi">10.1093/jtm/taab067</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Integrated gut virome and bacteriome dynamics in COVID-19 patients</article-title><source>Gut Microbes</source><year>2021</year><volume>13</volume><fpage>1</fpage><lpage>21</lpage></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Righi</surname><given-names>E</given-names></name><name><surname>Carnelutti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control</article-title><source>Expert Rev Anti Infect Ther</source><year>2018</year><volume>16</volume><fpage>749</fpage><lpage>61</lpage></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mba</surname><given-names>IE</given-names></name><name><surname>Nweze</surname><given-names>EI</given-names></name></person-group><article-title>Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects</article-title><source>World J Microbiol Biotechnol</source><year>2021</year><volume>37</volume><fpage>108</fpage></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>S</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Liu</surname><given-names>Y-Y</given-names></name></person-group><article-title>Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>5235</fpage></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>R</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name></person-group><article-title>Role of the Microbiome in the Pathogenesis of COVID-19</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><elocation-id>736397</elocation-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Varrette</surname><given-names>S</given-names></name><name><surname>Bouvry</surname><given-names>P</given-names></name><name><surname>Cartiaux</surname><given-names>H</given-names></name><etal/></person-group><source>Management of an academic HPC cluster: The UL experience</source><conf-name>2014 International Conference on High Performance Computing Simulation (HPCS)</conf-name><year>2014</year><fpage>959</fpage><lpage>67</lpage></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Sample collection and study design.</title><p>Schematic of the project study design, including cohort composition, and data analyses.</p></caption><graphic xlink:href="EMS156047-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Composition of the microbial community.</title><p><bold>a</bold>) Cladogram representing the microbial community profiles in COVID-19 patients (red) and control group (green). The outer rings represent the relative abundance (%) of the microbial community. <bold>b</bold>) Relative abundance of bacterial species significantly enriched in COVID-19 patients compared to the control group [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test]. <bold>c</bold>) Relative abundance of bacterial species significantly decreased in COVID-19 patients compared to the control group [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test].</p></caption><graphic xlink:href="EMS156047-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Abundance of virulence factors in the microbial community.</title><p><bold>a</bold>) Overall abundance (metagenome) of virulence factors encoded by the microbiome of COVID-19 patients and control group. The significance of the differential abundance is indicated with the adjusted <italic>p</italic>-value [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test]. <bold>b</bold>) Overall expression levels (metatranscriptomics) of virulence factors encoded by the microbiome in COVID-19 patients and the control group [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test]. <bold>c</bold>) Abundance and expression levels of MAG families where a significant increase in encoded and expressed virulence factors was observed in COVID-19 patients <italic>[adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test, *&lt;0.05, **&lt;0.01, ***&lt;0.001]. <bold>d</bold>) Abundance and expression levels of virulence factors in MAGs depicting taxonomic families only demonstrating an increased expression of virulence factors, with no significant difference observed at a metagenomic level [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test, * &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001].</p></caption><graphic xlink:href="EMS156047-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Abundance levels of antimicrobial resistance genes.</title><p><bold>a</bold>) Overall ARG abundance and expression levels for COVID-19 and control groups (boxplot), coupled with a breakdown of the respective abundance and expression levels to individual AMR categories [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test, * &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001]. <bold>b</bold>) ARG abundance (top) and expression levels (bottom) of individual AMR categories significantly increased in COVID-19 patients compared to the control group [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test, * &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001].</p></caption><graphic xlink:href="EMS156047-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Association of AMR with the microbial community.</title><p>Abundance (<bold>a</bold>) and expression (<bold>b</bold>) levels of ARGs and corresponding to AMR categories linked to MAGs. On top (boxplot) depicting the overall ARG abundance, below the average abundance of selected AMR categories per taxonomic family. The plot depicts taxonomic families in which overall a significant increase in abundance or expression of ARGs was observed [<italic>adj.p</italic> &lt; 0.05; Wilcoxon rank-sum test, * &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001].</p></caption><graphic xlink:href="EMS156047-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Assessing the <italic>infective competence</italic> of the gut microbiome.</title><p><bold>a</bold>) Correlation of gene abundances of AMR and virulence factors [R=0.52 and <italic>p</italic> &lt; 0.01; Spearman’s correlation] in COVID-19 patients (red) and the control group (green). <bold>b</bold>) Correlation of AMR and virulence factors gene expression levels [R=0.46 and <italic>p</italic> &lt; 0.01; Spearman’s correlation] in COVID-19 patients (red) and negative controls (green). <bold>c</bold>) Bubble plot depicting the <italic>infective competence</italic> via the log2 fold change of AMR and virulence factors between COVID-19 patients (red) and control group (green).</p></caption><graphic xlink:href="EMS156047-f006"/></fig></floats-group></article>